The FDA has fueled a pharmaceutical arms race in the painkiller market with the agency's decision last month to bar the sale and production of generic OxyContin, which has become one of the most widely abused opioids among Americans.
The life sciences industry is warming up to cloud computing, or so Medidata Solutions' first quarter financial results would seem to indicate.
Purdue Pharma and generic drugmaker Actavis have settled their patent suit over a special formulation of the painkiller OxyContin just 10 days the FDA banned generic versions that do not carry abuse resistant technology.
Medidata Solutions ($MDSO) has nailed down more business from a major pharma outfit. Purdue Pharma, known for making the pain drug OxyContin, has inked a multiyear deal with Medidata, expanding use of Medidata's software for clinical trials.
The drug companies say it's a safety issue. The generic competition, though, says it's about economics.
Infinity Pharmaceuticals has cut 20% of its employees as the drug developer advances its lead candidates without R&D dollars from Mundipharma International, the company revealed Tuesday. And the company also blamed its recent decision to end development of its lead anti-cancer compound saridegib for the staff cutbacks.
Venture backers have rallied behind Collegium Pharmaceutical to continue a late-stage trial for its extended-release version of oxycodone.
The reformulated version of OxyContin that became available last year appears to be delivering on Purdue's promise of an abuse-fighting trait touted--but not delivered--in the original formulation.
Officials from Kentucky and Florida want the makers of addictive painkillers to "take responsibility," because their current efforts at cooperating with law enforcement and educating consumers and
Will three times be a charm for Transcept Pharmaceuticals? The developer of neuroscience drugs ( $TSPT ) revealed late last night details of an expected complete response letter from the FDA for the